Rebekah John
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Rebekah John has a total of 21 co-authors. Here are the top co-authors by number of shared publications:
Anca D. Petrescu
Research Division, Central Texas Veterans Health Care System, Temple, Texas; Division of Pharmacology and Toxicology, College of Pharmacy, The University of Texas at Austin, Austin, Texas
1 shared publicationChristopher Johnson
Division of Gastroenterology, Department of Medicine, Baylor Scott and White Medical Center – Temple, Temple, Texas
1 shared publicationChristopher Naumann
Division of Gastroenterology, Department of Medicine, Baylor Scott and White Medical Center – Temple, Temple, Texas
1 shared publication- Courtney Shaver
Baylor Scott & White Research Institute , 3434 Live Oak St Ste 501, Dallas, TX 75204
1 shared publication Dawn M. Sears
Texas A&M Health Science Center College of Medicine, Bryan, Texas
1 shared publicationElaina Williams
Research Division, Central Texas Veterans Health Care System, Temple, Texas; Division of Pharmacology and Toxicology, College of Pharmacy, The University of Texas at Austin, Austin, Texas
1 shared publication
Latest Publications
- 6 July 2021
- Published by Taylor & Francis in Baylor University Medical Center Proceedings
- Vol. 34 (6) , 654-657
Prevalence of cannabinoid hyperemesis syndrome and its financial burden on the health care industry
Cannabis is the most commonly consumed recreational drug in the world. As more states legalize cannabis use in some form, the incidence of cannabinoid hyperemesis syndrome (CHS) is expected to rise. CHS is a constellation of symptoms including severe cyclical nausea and vomiting and epigastric or periumbilical abdominal pain as a result of long-term cannabis use. Recognizing the diagnosis and educating patients on the benefits of cessation is essential, as these patients often undergo extensive and repeated evaluations in the clinic, emergency department, and inpatient setting that could be avoided with extensive history taking and early recognition of the syndrome. In this study, we compared costs incurred by patients in various settings to determine if there is a difference between patients with and without CHS. Although there were not statistically significant cost differences between groups for all cost categories, it is clear that patients with CHS consume considerably more health care dollars than patients who deny cannabis use, and obtaining a detailed social history is imperative to prevent unnecessary workups and increased financial burden on the health care industry.
- 6 July 2021
- Published by Taylor & Francis in Baylor University Medical Center Proceedings
- Vol. 34 (6) , 654-657
Prevalence of cannabinoid hyperemesis syndrome and its financial burden on the health care industry
Cannabis is the most commonly consumed recreational drug in the world. As more states legalize cannabis use in some form, the incidence of cannabinoid hyperemesis syndrome (CHS) is expected to rise. CHS is a constellation of symptoms including severe cyclical nausea and vomiting and epigastric or periumbilical abdominal pain as a result of long-term cannabis use. Recognizing the diagnosis and educating patients on the benefits of cessation is essential, as these patients often undergo extensive and repeated evaluations in the clinic, emergency department, and inpatient setting that could be avoided with extensive history taking and early recognition of the syndrome. In this study, we compared costs incurred by patients in various settings to determine if there is a difference between patients with and without CHS. Although there were not statistically significant cost differences between groups for all cost categories, it is clear that patients with CHS consume considerably more health care dollars than patients who deny cannabis use, and obtaining a detailed social history is imperative to prevent unnecessary workups and increased financial burden on the health care industry.
- 13 April 2021
- Published by Taylor & Francis in Baylor University Medical Center Proceedings
- Vol. 34 (4) , 510-511
Eosinophilic pancreatitis presenting as possible malignancy
Eosinophilic pancreatitis is a rare form of chronic pancreatitis that is often mistaken for malignancy due to nonspecific presenting symptoms and noncontributory auxiliary exams. This clinical case report highlights a unique presentation of chronic pancreatitis. A middle-aged man developed abdominal pain, and repeat imaging showed an interval increase in size of a known pancreatic lesion. A core biopsy showed benign pancreatic tissue with eosinophilic-rich inflammation; IgE levels were also elevated. The patient was started on a prednisone taper, and repeat computed tomography 3 months later showed a decreased size of the pancreatic lesion. Correct and timely diagnosis of eosinophilic pancreatitis may avoid invasive unnecessary surgical procedures and allow for earlier initiation of appropriate therapy.
- 13 April 2021
- Published by Taylor & Francis in Baylor University Medical Center Proceedings
- Vol. 34 (4) , 510-511
Eosinophilic pancreatitis presenting as possible malignancy
Eosinophilic pancreatitis is a rare form of chronic pancreatitis that is often mistaken for malignancy due to nonspecific presenting symptoms and noncontributory auxiliary exams. This clinical case report highlights a unique presentation of chronic pancreatitis. A middle-aged man developed abdominal pain, and repeat imaging showed an interval increase in size of a known pancreatic lesion. A core biopsy showed benign pancreatic tissue with eosinophilic-rich inflammation; IgE levels were also elevated. The patient was started on a prednisone taper, and repeat computed tomography 3 months later showed a decreased size of the pancreatic lesion. Correct and timely diagnosis of eosinophilic pancreatitis may avoid invasive unnecessary surgical procedures and allow for earlier initiation of appropriate therapy.
- 5 February 2021
- Published by Taylor & Francis in Baylor University Medical Center Proceedings
- Vol. 34 (3) , 399-400
Diagnosis and treatment of malignant-appearing arteriovenous malformation
Arteriovenous malformations (AVM) are most commonly found in the gastrointestinal tract, and presentation can range from asymptomatic to massive gastrointestinal hemorrhage. This case highlights a unique presentation of AVMs. During a screening colonoscopy, a 5-cm mass was discovered in the transverse colon encompassing 25% to 50% of the circumference of the lumen. Biopsies showed polypoid AVM with overlying inflammatory polyps without evidence of malignancy or dysplasia. There are many treatment options for AVM removal. In this case, since suspicion for malignancy was high, the patient underwent surgery and will be closely monitored.
- 5 February 2021
- Published by Taylor & Francis in Baylor University Medical Center Proceedings
- Vol. 34 (3) , 399-400
Diagnosis and treatment of malignant-appearing arteriovenous malformation
Arteriovenous malformations (AVM) are most commonly found in the gastrointestinal tract, and presentation can range from asymptomatic to massive gastrointestinal hemorrhage. This case highlights a unique presentation of AVMs. During a screening colonoscopy, a 5-cm mass was discovered in the transverse colon encompassing 25% to 50% of the circumference of the lumen. Biopsies showed polypoid AVM with overlying inflammatory polyps without evidence of malignancy or dysplasia. There are many treatment options for AVM removal. In this case, since suspicion for malignancy was high, the patient underwent surgery and will be closely monitored.
- 1 March 2020
- Published by Elsevier in The American Journal of Pathology
- Vol. 190 (3) , 586-601
Coordinated Targeting of Galanin Receptors on Cholangiocytes and Hepatic Stellate Cells Ameliorates Liver Fibrosis in Multidrug Resistance Protein 2 Knockout Mice
- 1 March 2020
- Published by Elsevier in The American Journal of Pathology
- Vol. 190 (3) , 586-601
Coordinated Targeting of Galanin Receptors on Cholangiocytes and Hepatic Stellate Cells Ameliorates Liver Fibrosis in Multidrug Resistance Protein 2 Knockout Mice